Asset profile
REGN5459
Multispecific antibody
Evidence outlook · lead readout
NCT04083534 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT04083534: The study treated 43 participants with REGN5459 alone without randomization, blinding, or a comparator arm. Its clinical response endpoint and safety outcomes have not yet been reported, so the study provides limited controlled evidence.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.